Coastlands Capital Reports Acquisition of $309,921.66 in Bolt Biotherapeutics Common Shares
- Coastlands Capital, a 10% owner of Bolt Biotherapeutics, acquired 53,094 common shares, bringing its indirect beneficial holdings to 515,510 shares.
- Purchases comprised 33,094 shares at $5.89 per share and 20,000 shares at $5.7499 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-129252), on November 17, 2026, and is solely responsible for the information contained therein.